Newly Formed Elixinol Global Begins Trading on Australian Stock Exchange
Colorado-Based Elixinol LLC, joins forces with Hemp Foods Australia and Elixinol Australia to form Elixinol Global
SYDNEY, Australia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Intending to serve the growing global cannabis market, Elixinol Global (ASX: EXL), comprised of Elixinol LLC, with distribution of hemp-based CBD products in 27 countries, Hemp Foods Australia and Elixinol Pty. Elixinol Global provides investors with access to global markets in the emerging sectors of hemp-based dietary supplements and skin care, hemp food products and medical cannabis products.
Elixinol Global began trading on the Australian Stock Exchange starting January 8, 2018.
"With global exports of Australian medical marijuana now approved, the world will soon have single-source access to best in class medical marijuana and hemp products from Elixinol, one of the world's most trusted brands," said Paul Benhaim, CEO of Elixinol Global.
"Paul Benhaim, widely recognized as one of the earliest global hemp advocates, is a founder in all three companies. It is time to offer investors an opportunity to take advantage of the collective footprint in this revolutionary emerging global market while capitalizing on potential efficiencies," said Ron Dufficy, Elixinol Global's Chief Financial Officer.
Under the new organization, Australian-based Hemp Foods will continue to be a global manufacturer and distributor of quality hemp food products and skin care. Elixinol LLC will continue to be the global bulk and retail provider of hemp-based cannabidiol (CBD) dietary supplements and topical products from US and European hemp. Elixinol Pty will provide the globe access to medical marijuana exports from Australia.
"As the cannabis market grows, it will be ever important to health-conscious consumers to know and trust their CBD and THC products. Elixinol LLC and Hemp Foods have been leading the industry with best in class sourcing and testing since their respective inceptions and Elixinol Pty will provide the same assurances for global medical marijuana patients," said Benhaim
"This means our global customers will see increased access to the same great products they're using in their daily lives, with a continued focus on research and development of new products that meet the demands of active, healthy lifestyles," continued Benhaim.
"We've worked very hard to make Elixinol the most trusted CBD brand in the world Elixinol Global is only the beginning of expanded opportunities for investors, strategic partners and our global customers," continued Benhaim.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The ASX has not reviewed, approved or disapproved the content of this press release.
About Elixinol Global
Elixinol Global is publically traded on the ASX under ELX. The holding company has a global presence in the cannabis industry including hemp, CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global's brands include: Elixinol LLC, founded in 2014, is a global manufacturer and distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA Founded in 1999, Hemp Foods Australia Pty Ltd is the largest hemp food wholesaler, retailer, manufacturer and exporter in the Southern Hemisphere of bulk and branded raw materials and finished products. Elixinol Pty Ltd, founded in 2014, to participate in the emerging Australian medicinal cannabis market.
Chief Executive Officer
+61 407 767 709
Chief Financial Officer and Company Secretary
+61 428 881 718
Photos accompanying this announcement are available at
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elixinol via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21 | Pressemelding
BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad
Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer18.10.2018 14:03 | Pressemelding
NEW YORK and CLEVELAND, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of João Siffert, M.D. as Head of Research and Development and Chief Medical Officer. As a result, former Chief Medical Officer Juan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. The Company also announced the appointment of Neena Patil, J.D. as General Counsel and Corporate Secretary. Both Dr. Siffert and Ms. Patil report to Chief Executive Officer, Carsten Thiel, Ph.D. “I am very pleased to welcome João and Neena to Abeona, and confident in their abilities to make important contributions to the future growth of our company,” said Dr. Thiel. “João has an ideal blend of clinical, scientific, and regulatory experience to reference as we look to advance our clinical and pre-clinical can
Meltwater and Dow Jones Announce Global Partnership to Provide Premium Content18.10.2018 14:00 | Pressemelding
SAN FRANCISCO and NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Meltwater, a global leader in media intelligence, today announces the launch of a partnership with Dow Jones, a global provider of news and business information, to provide premium licensed content from Dow Jones Factiva into the Meltwater Media Intelligence platform. This partnership will give Meltwater’s PR and communications clients the ability to monitor and analyze premium licensed content across thousands of Factiva news sources globally, including: The Wall Street Journal, America’s largest newspaper by paid circulation; Barron’s; MarketWatch; and Dow Jones Newswires. “Meltwater provides our clients with the most comprehensive content network globally, across news, social media and broadcast media. This new Dow Jones partnership will further strengthen our leadership position and allow our clients to access licensed content from some of the most highly-respected news outlets in the world. We’re excited about this part
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting18.10.2018 13:30 | Pressemelding
EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia or poster session. Data to be presented across the Alzheimer’s disease clinical development portfolio, including aducanumab, BAN2401 and elenbecestat CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced it will present data from its Alzheimer’s disease (AD) clinical development portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in Barcelona, Spain (October 24-27). The data being presented are part of Biogen’s ongoing research programs targeting possible causes of the disease through multiple modalities. “We are excited to engage with the scientific community at CTAD, to share learnings from our Alzheimer’s disease clinical research and to learn from the work of our colleagues around the world. We have hopes that our
SEMAFO Provides Notice of Third Quarter 2018 Results Release and Conference Call 18.10.2018 13:30 | Pressemelding
MONTREAL, Oct. 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX, OMX: SMF) invites you to participate in a conference call on November 7, 2018 at 10:00 AM EST with senior management during which they will review the Corporation's third quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the third quarter 2018 will be released on November 6 after market hours and will be available in the “Investor Relations” section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO’s website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 2823689 Expiration: December 7, 2018 About SEMAFO SEMAFO is a Canadian-b
Biome Grow Announces Listing on the Frankfurt Stock Exchange under symbol 60TA18.10.2018 13:30 | Pressemelding
TORONTO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- (CSE: BIO) – Biome Grow (“Biome” or the “Company”) (CSE:BIO) is pleased to announce that the Company’s common shares have been listed on the Frankfurt Stock Exchange under the trading symbol “6OTA”. The Company’s common shares continue to be listed on the Canadian Securities Exchange (“CSE”) under the trading symbol “BIO”. “Biome is developing its production base in Canada with an eye to becoming a leader in the international medical cannabis market. Listing on the Frankfurt Stock Exchange will give Biome increased access to European and other international investors and positions Biome well for international growth and development opportunities,” said CEO Khurram Malik. The Frankfurt Stock Exchange is one of the world’s largest trading centres for securities. With a share in turnover of around 90 per cent, it is the largest of Germany’s seven stock exchanges and it is an international trading centre, which is reflected in the structure of its
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom